{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper 95% confidence interval were not reached.","groupId":"OG000","lowerLimit":"8.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive:\n\nCycle 1:\n\n250 mg/m\\^2 rituximab IV on days 1 and 8, 2 mg (5.0mCi of In-111) Indium (In-111 ibritumomab tiuxetan) IV over 10 minutes on day 1, 0.4 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8\n\nCycle 2 (Cycle 2 delivered 24-36 weeks after Cycle 1):\n\n250 mg/m\\^2 rituximab IV on days 1 and 8, 2 mg (5.0mCi of In-111) Indium (In-111 ibritumomab tiuxetan) IV over 10 minutes on day 1, 0.4 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8.\n\nPatients also receive:\n\n480 mcg filgrastim (G-CSF) subcutaneously (SC) daily when ANC is less than 1500.\n\n50 micrograms/kg Interleukin-11 SC when PLT counts less than 150,000.","id":"OG000","title":"Treatment : Dose Level 6"}],"paramType":"MEDIAN","populationDescription":"Phase II portion of the study. One patient out of the 39 was deemed ineligible and was not included in survival analysis.","reportingStatus":"POSTED","timeFrame":"From registration to death due to any cause, assessed up to 5 years","title":"Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"years"}